---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-005016"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:41:06.512708+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio reports $164M cash, expands rese-cel trials into MS, MG, PV; FDA meeting planned 1H25

## Summary
- Unaudited cash $164M as of Dec 31, 2024; funds operations into H1 2026.
- 21 patients enrolled across 44 RESET sites in US/Europe; safety data: 90% no CRS/grade 1, 90% no ICANS.
- First patients enrolled in RESET-PV (no preconditioning) and RESET-MG; RESET-MS IND cleared with Fast Track.
- Expanded CDMO agreement with Lonza for clinical supply from H2 2025.
- Plans to meet FDA in 1H 2025 to align on registrational trial designs.

## SEC filing metadata
- accession: 0001193125-25-005016
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312525005016/0001193125-25-005016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312525005016/d781872d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-005016
- JSON: https://secwatch.observer/filing/0001193125-25-005016.json
- Plain text: https://secwatch.observer/filing/0001193125-25-005016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.